Evaxion completes phase 2 trial extension for cancer vaccine EVX-01

April 7, 2026 12:34 PM

Evaxion A/S (NASDAQ: EVAX) announced the completion of a one-year extension for its phase 2 trial evaluating personalized cancer vaccine ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found